<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rett syndrome: Treatment and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rett syndrome: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Rett syndrome: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca J Schultz, PhD, APRN, CPNP-PC, FAES</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernhard Suter, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2079850073"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Rett syndrome (RTT) is a neurodevelopmental disorder that occurs almost exclusively in females. After a brief period of initially normal development, affected patients experience loss of speech and purposeful hand use, stereotypic hand movements, and gait abnormalities. Additional manifestations include deceleration of head growth, seizures, autistic features, and breathing abnormalities. RTT is not a degenerative disorder. Rather, it is a progressive disorder with multisystem symptom evolution over the lifespan [<a href="#rid1">1</a>].</p><p>This topic will review the treatment and prognosis of RTT. Other aspects of RTT are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6178.html" rel="external">"Rett syndrome: Genetics, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2938635402"><span class="h1">COUNSELING AND SUPPORT</span><span class="headingEndMark"> — </span>RTT is a chronic and devastating neurodevelopmental disorder that has a tremendous impact on affected individuals, families, and caregivers. The first important step in management is confirming the diagnosis of RTT (see  <a class="medical medical_review" href="/z/d/html/6178.html" rel="external">"Rett syndrome: Genetics, clinical features, and diagnosis", section on 'Diagnosis'</a>). This is often a relief to families and caregivers who have searched for an explanation for the child's problems. It may also be the beginning of the grief process for the loss of a normal child. At the time of diagnosis, anticipatory guidance should be provided regarding the spectrum of clinical problems. All parents should be taught cardiopulmonary resuscitation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Education and healthcare</strong> – Support of a comprehensive educational program for RTT individuals may require completing forms, informing teachers and therapists about RTT, and promoting a communication program rather than speech therapy alone [<a href="#rid2">2</a>]. Since expected survival in RTT is beyond the fifth decade (see <a class="local">'Prognosis'</a> below), issues pertaining to adulthood and adult health care should be discussed with the family and guardians, including identification of appropriate health care providers for children and adults with RTT, guardianship, and long-term financial planning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Caregiver burden</strong> – Individuals with RTT are totally dependent for all activities of living throughout their life. In our experience, most individuals with RTT live at home even as adults. Clinicians have long recognized the life-long burden of RTT on families and caregivers, but there are few systematic studies investigating caregiver burden. Careful monitoring of the ability of older parents to care for their adult daughters with RTT is important to parental health, and supports the care of those older individuals with RTT. One study found that caregiver burden increased as caregiver health declined [<a href="#rid3">3</a>]. There was a stronger association between the caregiver burden and parental health than with demands related to the individual with RTT. Another report found that mothers of individuals with RTT had lower physical and mental health scores compared with standard average scores [<a href="#rid4">4</a>]. These studies highlight the importance of assessing the physical and mental well-being of RTT caregivers. Encouraging parents to take "time off" and utilize respite care are important to their mental and physical health.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resources and advocacy</strong> – Resources and information about advocacy, ongoing research, and care of individuals affected by RTT are available from national and local organizations, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.rettsyndrome.org%2F&amp;token=gHgfAPQIBJZBPDYSeLaRCv8APFVRNizSHOqVTh9f7Su2rly1vFpe1d6khycwYpgi&amp;TOPIC_ID=109840" target="_blank">International Rett Syndrome Foundation</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Freverserett.org%2F&amp;token=b%2BCAAzStFFn2YfKmvr1ev1wggpu6SfziaE%2BuqKXP4NevALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=109840" target="_blank">Rett Syndrome Research Trust</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Frettland.org%2F&amp;token=jkQ6Qz%2BQRbkT%2Br4iNr07sXPOrDG%2BI2%2FGJuCa9t0GA1E%3D&amp;TOPIC_ID=109840" target="_blank">Rettland Foundation</a></p><p></p><p class="headingAnchor" id="H3102288875"><span class="h1">DISEASE-MODIFYING THERAPY</span></p><p class="headingAnchor" id="H3964671202"><span class="h2">Trofinetide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="140989" href="/z/d/drug information/140989.html" rel="external">Trofinetide</a> was approved in the United States by the FDA in March 2023 for the treatment of RTT in adults and children two years of age and older [<a href="#rid5">5</a>]. It is the first disease-modifying treatment available for RTT. FDA approval was primarily based on results from the LAVENDER trial, discussed below.</p><p>Given the short duration of the LAVENDER study, the modest effect sizes demonstrated, and the high rate of adverse effects (mainly diarrhea), we advise that treatment decisions regarding <a class="drug drug_general" data-topicid="140989" href="/z/d/drug information/140989.html" rel="external">trofinetide</a> should be individualized and guided by shared decision-making involving the treating clinician, family, and caregivers. This process involves discussions of the benefits and risks of therapy, and accounts for patient values and preferences.</p><p><a class="drug drug_general" data-topicid="140989" href="/z/d/drug information/140989.html" rel="external">Trofinetide</a> is a synthetic analog of glycine-proline-glutamate (GPE), the N-terminal tripeptide of the insulin-like growth factor 1 (IGF-1). Its mechanism of action is not completely understood, but purported actions include anti-inflammatory, anti-oxidant, and trophic effects that stabilize dendritic morphology, synaptic protein synthesis, and neuronal signaling [<a href="#rid6">6,7</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The 12-week LAVENDER trial randomly assigned 187 females (5 to 20 years of age) with typical RTT to <a class="drug drug_general" data-topicid="140989" href="/z/d/drug information/140989.html" rel="external">trofinetide</a> (dosed based on patient weight) or matching placebo in a 1:1 ratio [<a href="#rid8">8,9</a>]. The trial used the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Clinical Global Impressions-Improvement (CGI-I) to assess outcomes. The RSBQ is a 45-item rating scale rated by caregivers that measures RTT symptoms and signs, including breathing, hand movements or stereotypies, repetitive behaviors, night-time behaviors, vocalizations, facial expressions, eye gaze, and mood; lower scores indicate less severe RTT. The CGI-I is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) rated by clinicians; lower scores indicate improvement.</p><p></p><p class="bulletIndent1">At 12 weeks, there was greater improvement from baseline on the RSBQ for patients assigned to <a class="drug drug_general" data-topicid="140989" href="/z/d/drug information/140989.html" rel="external">trofinetide</a> compared with placebo (least-squares [LS] mean change from baseline, -4.9 versus -1.7, LS mean treatment difference -3.2, 95% CI -5.7 to -0.6) and the CGI-I (mean score 3.5 versus 3.8, LS mean treatment difference 0.3, 95% CI -0.5 to -0.1) [<a href="#rid8">8</a>]; the number of patients considered to have clinically significant improvement (as represented by a CGI-I score of 2 or 1) was greater in the trofinetide group (13 percent, versus 4.7 percent in the placebo group) [<a href="#rid10">10</a>]. However, the available data provide no information regarding which specific symptoms were considered meaningfully improved.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="140989" href="/z/d/drug information/140989.html" rel="external">Trofinetide</a> led to improvements in two preceding short-term trials, one in adults with RTT and one in a population with more pediatric patients [<a href="#rid6">6,11</a>]. Whether trofinetide results in clinically meaningful long-term benefit for a majority of individuals affected by RTT remains to be established.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – In clinical trials, most patients (85 percent) treated with <a class="drug drug_general" data-topicid="140989" href="/z/d/drug information/140989.html" rel="external">trofinetide</a> developed diarrhea, which was generally mild or moderate in severity, leading to treatment discontinuation in 18 percent of patients [<a href="#rid8">8,12</a>]. Vomiting was seen in approximately 30 percent. Weight loss greater than 7 percent from baseline affected 12 percent of patients.</p><p></p><p class="bulletIndent1">Patients should be advised to stop laxatives prior to treatment. Diarrhea may be manageable in some patients with dose adjustments antidiarrheal treatment and increased oral fluids as needed; patients should be monitored for hydration status [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">There are no human data on risks of <a class="drug drug_general" data-topicid="140989" href="/z/d/drug information/140989.html" rel="external">trofinetide</a> with use during pregnancy or lactation. Animal data suggest no adverse developmental effects with trofinetide administration [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – <a class="drug drug_general" data-topicid="140989" href="/z/d/drug information/140989.html" rel="external">Trofinetide</a> is formulated as an oral solution (200 mg/mL) and is dosed according to patient weight [<a href="#rid8">8</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>9 kg to &lt;12 kg: 5000 mg twice daily (25 mL twice daily)</p><p class="bulletIndent2"><span class="glyph">•</span>12 kg to &lt;20 kg: 6000 mg twice daily (30 mL twice daily)</p><p class="bulletIndent2"><span class="glyph">•</span>20 kg to &lt;35 kg; 8000 mg twice daily (40 mL twice daily)</p><p class="bulletIndent2"><span class="glyph">•</span>35 kg to &lt;50 kg: 10,000 mg twice daily (50 mL twice daily)</p><p class="bulletIndent2"><span class="glyph">•</span>50 kg or more: 12,000 mg twice daily (60 mL twice daily)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="140989" href="/z/d/drug information/140989.html" rel="external">Trofinetide</a> can be given orally, by gastrostomy tube, or by gastrojejunal tube if administered through the G-port. There are no contraindications.</p><p></p><p class="headingAnchor" id="H2686011564"><span class="h2">Investigational therapies</span><span class="headingEndMark"> — </span>Studies in Mecp2-mutant mice suggest potential therapeutic targets [<a href="#rid13">13-15</a>]. Potentially promising approaches include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glatiramer acetate</strong> – An open-label trial of 10 females with RTT, age ≥10 years found that treatment with <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a> was associated with improved gait velocity [<a href="#rid16">16</a>]. Glatiramer is a mixture of four amino acid polymers that has been approved for treatment of multiple sclerosis. The finding of improved gait in RTT requires confirmation in larger, more rigorous trials.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gene therapy</strong> – In theory, inserting a working "normal" copy of the <em>MECP2</em> gene into the MeCP2-deficient cells could lead to significant improvements in RTT signs and symptoms. Genetic therapies to boost MeCP2 protein levels are being explored but have significant hurdles to overcome [<a href="#rid17">17-20</a>].</p><p></p><p class="headingAnchor" id="H1989743613"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Apart from <a class="drug drug_general" data-topicid="140989" href="/z/d/drug information/140989.html" rel="external">trofinetide</a>, no specific therapy is available for RTT. Management consists of treating the associated conditions. A multidisciplinary approach is optimal. Aggressively addressing current health problems and multisystem screening for evolving health problems is important to improve the wellbeing and quality of life of patients with RTT and their families and caregivers [<a href="#rid1">1</a>]. Nutritional, gastrointestinal, and motor problems are nearly universal among patients with RTT. These individuals also can be affected by seizures and nonepileptic behaviors, which should be identified to optimize therapy. Addressing psychosocial function, including that of the family and caregivers, and educational support are also essential. (See <a class="local">'Counseling and support'</a> above.)</p><p class="headingAnchor" id="H3742049020"><span class="h2">Nutrition</span><span class="headingEndMark"> — </span>Somatic growth should be closely monitored with attention to weight, height, and body mass index [<a href="#rid1">1,21</a>]. Nutritional screening is recommended every six months, with particular attention to energy, protein, fluids, sodium, potassium, calcium and vitamin D intake [<a href="#rid1">1</a>].</p><p>A high calorie, well-balanced diet should be provided with vitamins and minerals at the recommended dietary allowance. Energy intake should be increased with high-calorie supplements, either orally or by gastrostomy feeding, if needed to maintain adequate growth. Oromotor function should be assessed by videofluoroscopy in children who have choking, decreased control of secretions, frequent upper or lower respiratory infections, or weight loss. An individualized treatment plan should be developed including appropriate food and beverage consistencies, positioning, and the use of selected feeding utensils.</p><p>Nutritional support improves growth in RTT, confirming the importance of dietary energy intake. In a cohort of 92 females with RTT, gastrostomy placement for nutritional supplementation was associated with statistically significant increases in Z score slopes for height, weight, and body mass index [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H538945082"><span class="h2">Gastrointestinal dysfunction</span><span class="headingEndMark"> — </span>Patients with a history of eating difficulty, eructation, emesis, or irritability should be evaluated for possible gastroesophageal reflux disease, delayed gastric emptying, or biliary tract disease [<a href="#rid1">1</a>]. The Gastrointestinal Health Questionnaire is a validated tool that can be used to assess gastrointestinal health, mood and behaviors, and parent and caregiver concerns in these individuals [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/5900.html" rel="external">"Management of gastroesophageal reflux disease in children and adolescents"</a>.)</p><p>Constipation can be a severe and chronic problem for many patients. One approach is a program of daily prophylaxis. Options include <a class="drug drug_general" data-topicid="10231" href="/z/d/drug information/10231.html" rel="external">polyethylene glycol 3350</a> (17 g) dissolved in 8 oz of water, juice, or milk daily with titration up or down to tolerance, or <a class="drug drug_general" data-topicid="9582" href="/z/d/drug information/9582.html" rel="external">magnesium hydroxide</a> 0.5 to 1.0 mL/kg once a day with titration down to tolerance.</p><p class="headingAnchor" id="H1889683036"><span class="h2">Bone quality and fractures</span><span class="headingEndMark"> — </span>Low bone mineral density is common and may lead to fractures. Consensus guidelines from an expert group recommend the following [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A comprehensive assessment of bone health for patients with RTT that includes fracture history and assessment for risk factors such as more severe pathogenic variants in <em>MECP2</em> (R168X, R255X, R270X, or T158M), antiepileptic medications, pubertal development, mobility level, dietary intake, and biochemical bone markers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone densitometry at baseline, with subsequent monitoring every one to two years according to the presence of risk factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lateral spine radiographs.</p><p></p><p>To improve bone health, the following measures are recommended [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased physical activity to increase muscle strength and bone density.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Calcium supplementation when dietary intake is low.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin D supplementation when levels are below normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bisphosphonate therapy for children and adolescents who meet criteria for osteoporosis from the International Society for Clinical Densitometry, which require both a clinically significant history of bone fractures and low bone mineral content or low bone mineral density [<a href="#rid25">25,26</a>]. (See  <a class="medical medical_review" href="/z/d/html/2056.html" rel="external">"Overview of dual-energy x-ray absorptiometry", section on 'Children'</a>.)</p><p></p><p class="headingAnchor" id="H3136662869"><span class="h2">Scoliosis</span><span class="headingEndMark"> — </span>Scoliosis should be identified as early as possible. However, the optimal treatment of scoliosis in RTT is uncertain, and high-quality evidence supporting management strategies is limited. Guidelines for the management of scoliosis in patients with RTT, published in 2009, are based largely upon consensus opinion [<a href="#rid27">27</a>]. The guidelines recommend a life-span approach that starts prior to the development of scoliosis and involves a comprehensive management team that includes medical, surgical, and physical therapy specialists. Physical assessment of the spine is recommended at least every six months. Referral to an orthopedic surgeon is advised if curvature exceeds 20° [<a href="#rid1">1</a>].</p><p>Although there is no evidence that physiotherapy can prevent progression of scoliosis, the guidelines recommend a therapy program that aims to prolong ambulation and maintain range of motion and proper seating [<a href="#rid27">27</a>]. Bracing to control progression of the scoliosis does not appear to be helpful [<a href="#rid27">27-29</a>], but it may be used for truncal stability [<a href="#rid27">27</a>].</p><p>Retrospective evidence suggests that surgical management can be beneficial for certain cases of scoliosis [<a href="#rid30">30-32</a>]; the guidelines recommend consideration of spinal fusion when the Cobb angle is 40 to 50 degrees [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/6286.html" rel="external">"Adolescent idiopathic scoliosis: Clinical features, evaluation, and diagnosis", section on 'Cobb angle'</a>.)</p><p class="headingAnchor" id="H2583163364"><span class="h2">Seizures</span><span class="headingEndMark"> — </span>Seizures may occur during sleep or may not be recognized by caregivers. Conversely, many behavioral events identified by parents as seizures are nonepileptic. Thus, video-electroencephalography (EEG) monitoring may be necessary to differentiate nonepileptic behavioral events from actual seizures and to identify unrecognized seizures.</p><p>Most seizures associated with RTT are easily controlled and respond to standard antiepileptic medications. Nevertheless, some patients with RTT have intractable seizures, and polytherapy with three or more anticonvulsant medications has been used in up to 19 percent of patients with RTT and seizures [<a href="#rid33">33,34</a>]. A ketogenic diet [<a href="#rid35">35-37</a>] or vagus nerve stimulator [<a href="#rid38">38,39</a>] may improve intractable seizures. (See  <a class="medical medical_review" href="/z/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy"</a> and  <a class="medical medical_review" href="/z/d/html/2229.html" rel="external">"Vagus nerve stimulation therapy for the treatment of epilepsy"</a>.)</p><p>Hormonal therapy or treatment with <a class="drug drug_general" data-topicid="10115" href="/z/d/drug information/10115.html" rel="external">vigabatrin</a> may be helpful in patients with infantile spasms. (See  <a class="medical medical_review" href="/z/d/html/6186.html" rel="external">"Infantile epileptic spasms syndrome: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H3102677171"><span class="h2">Breathing disturbances</span><span class="headingEndMark"> — </span>There is no known treatment for the awake breathing disturbances with alternating hyperventilation and apneic episodes that is often associated with RTT. (See  <a class="medical medical_review" href="/z/d/html/6178.html" rel="external">"Rett syndrome: Genetics, clinical features, and diagnosis", section on 'Disorders of respiratory control'</a>.)</p><p>In our experience, treatment with supplemental oxygen or rebreathing of carbon dioxide has not resulted in improvement; rebreathing has occasionally worsened the apnea. <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">Naltrexone</a> and <a class="drug drug_general" data-topicid="9580" href="/z/d/drug information/9580.html" rel="external">magnesium citrate</a> have been reported to lessen the severity of disordered breathing. In our experience, these have been beneficial to a small number of females. Serotonin agonists such as <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a> have been suggested as potential treatments for the awake breathing abnormalities observed in RTT based upon studies in a mouse model of RTT [<a href="#rid40">40-43</a>]. However, a randomized controlled trial of a serotonin agonist (sarizotan) in patients with RTT who have respiratory abnormalities was discontinued due to lack of efficacy [<a href="#rid44">44</a>].</p><p>Apnea during sleep is not characteristic of RTT. It should be evaluated as in any patient with sleep apnea. (See  <a class="medical medical_review" href="/z/d/html/6363.html" rel="external">"Evaluation of suspected obstructive sleep apnea in children"</a>.)</p><p class="headingAnchor" id="H660435903"><span class="h2">Cardiac abnormalities</span><span class="headingEndMark"> — </span>An electrocardiogram (ECG) should be obtained when the diagnosis of RTT is made. If the QTc interval is &gt;0.45, a cardiologist should be consulted. The ECG should be monitored annually.</p><p>Medications associated with prolongation of the QT interval (eg, tricyclic antidepressants, <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>) should be avoided. Beta blockers such as <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> may be appropriate in some cases. (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Drugs that prolong the QT interval'</a>.)</p><p class="headingAnchor" id="H670679252"><span class="h2">Sleep disturbance</span><span class="headingEndMark"> — </span>Evaluation of sleep disturbance should include characterization of night and daytime routines, time of occurrence and related factors, and impact on the family and caregivers. Specific disorders that disturb sleep should be considered, such as sleep apnea secondary to tonsillar and/or adenoidal hypertrophy, gastroesophageal reflux, and seizures.</p><p>Behavioral intervention should be attempted to treat dysfunctional sleep patterns. Good sleep hygiene should be encouraged [<a href="#rid45">45,46</a>]. Measures include maintaining regular day and night routines, allowing the child only to sleep in bed, establishing a bedtime conducive to rapid sleep onset, removing the child from the bed if she does not fall asleep within one hour, and avoiding daytime sleep except for scheduled naps [<a href="#rid47">47</a>]. Other measures that may be helpful are taking a warm bath one to two hours before sleep, avoiding caffeine, exercising no later than three to four hours before bedtime, and following a routine bedtime ritual. Bright light exposure in the early morning promotes early sleep time, while evening exposure promotes later sleep time and should be avoided [<a href="#rid48">48</a>].</p><p>Pharmacologic agents are not consistently successful at correcting sleep disorders. Many disrupt the normal sleep architecture and/or have persistent effects on the following day. Alternative therapies may include short-acting, non-benzodiazepine receptor agonists such as <a class="drug drug_general" data-topicid="10334" href="/z/d/drug information/10334.html" rel="external">zaleplon</a> or <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">zolpidem</a>. Other sleep-inducing agents such as <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">trazodone</a> and <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a> have also been utilized. Melatonin has improved sleep disturbances in some patients with RTT, but further studies are needed before it can be recommended [<a href="#rid49">49-51</a>].</p><p class="headingAnchor" id="H3262013999"><span class="h2">Motor dysfunction</span><span class="headingEndMark"> — </span>A program of physical, occupational, and communication therapy should be provided for patients with RTT. Physical therapy is thought to promote ambulation and balance, prevent or retard the development of contractures, and control deformities [<a href="#rid52">52,53</a>]. A 2020 systematic review and meta-analysis of 22 studies found some evidence that multimodal individualized physical therapy programs help preserve autonomy and quality of life [<a href="#rid54">54</a>]. Modalities included applied behavior analysis, conductive education, environmental enrichment, traditional physiotherapy with or without aids, hydrotherapy, treadmill, music therapy, computerized systems, and sensory-based treatment.</p><p>The goal of occupational therapy is to promote purposeful use of the hands. Hand stereotypies can often be diminished by providing elbow or hand restraints. It may only be necessary to restrain the non-dominant hand or elbow. In several small series, splinting to inhibit repetitive hand activity was associated with improvements such as increased socialization and interaction with the environment [<a href="#rid55">55-58</a>]. In our clinical experience, many therapists employ this technique with success. However, larger studies evaluating the effectiveness of hand splints are needed.</p><p>Communication therapy may enhance communication skills. Observation-based assessment approaches may be useful for communication intervention planning.</p><p>Other types of therapy may also be helpful, although few data are available to support their use. Music therapy may facilitate sustained focus, attention, and improve interaction [<a href="#rid59">59-61</a>]. Hydrotherapy may promote movement and balance. Horseback riding may promote balance and protective responses that help maintain mobility and avert falls.</p><p class="headingAnchor" id="H3241508740"><span class="h2">Reproductive issues</span><span class="headingEndMark"> — </span>Females with RTT go through puberty, menstruate, and may become pregnant. Issues and options concerning birth control and hygiene should be discussed with parents or guardians of patients with RTT.</p><p class="headingAnchor" id="H1425539486"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The natural history of typical RTT in childhood is well described (see  <a class="medical medical_review" href="/z/d/html/6178.html" rel="external">"Rett syndrome: Genetics, clinical features, and diagnosis", section on 'Typical RTT'</a>). After a period of initially normal development, affected children experience regression with partial or complete loss of speech and purposeful hand use, and onset of stereotypic hand movements, gait abnormalities, and other manifestations of RTT. Following the regression phase, there is a period of some recovery of nonverbal communication, with improved eye contact and nonverbal interactions with the environment. This is followed by a slow, insidious deterioration in gross motor function through adulthood [<a href="#rid62">62,63</a>].</p><p>The type of pathogenic variant in <em>MECP2</em> appears to impact outcome in RTT, as reviewed separately (see  <a class="medical medical_review" href="/z/d/html/6178.html" rel="external">"Rett syndrome: Genetics, clinical features, and diagnosis", section on 'Genotype-phenotype correlations'</a>). The R133C, R294X, and C-terminal truncating mutations are associated with somewhat milder disease, while the R168X, R255X, R270X, and T158M mutations are associated with more severe disease.</p><p>Most patients with RTT survive well into adulthood [<a href="#rid63">63-66</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of the North American RTT database comprising patients with typical RTT (n = 1648) and atypical RTT (n = 259), the median survival of patients with typical RTT was approximately age 45 years [<a href="#rid64">64</a>]. Survival for individuals with atypical RTT was significantly longer than for those with typical RTT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 1189 participants in the Rett Syndrome Natural History study recruited from 2006 to 2015, survival into the fifth decade was typical; survival for classic and atypical RTT at age 45 years was &gt;75 percent [<a href="#rid65">65</a>]. During the nine-year follow-up period, there were a total of 51 deaths affecting individuals ranging in age from approximately 4 to 67 years. Mortality affected 36 females (4 percent) with classic RTT and 5 females (6 percent) with atypical severe RTT. All females with atypical mild RTT remained alive during this period. Most deaths were caused by cardiopulmonary factors. Risk factors associated with mortality in classic RTT included inability to walk, low body weight, and frequent seizures. Specific <em>MECP2</em> variants were not significantly associated with mortality. This report suggested that aggressive health management and therapeutic approaches could further improve the prognosis for patients with RTT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report of 396 females with RTT who were followed for up to 20 years, the likelihood of survival at age 25 years was approximately 72 percent, and at age 37 years was approximately 60 percent [<a href="#rid66">66</a>]. Information on the cause of death was available for 57 deceased females; the most common causes were respiratory illnesses (lower respiratory tract infection, aspiration, asphyxiation, and respiratory failure) in 82 percent, and seizure-related causes in 5 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are only a limited number of studies of RTT in adulthood. In a combined cross-sectional cohort of 423 cases of females with RTT ≥18 years of age, the following outcomes were reported [<a href="#rid66">66</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The median age of the cohort was 25 years (range 18 to 54 years)</p><p class="bulletIndent2"><span class="glyph">•</span>The proportion living in their parental home was 71 percent; the remainder were living in group homes or institutions</p><p class="bulletIndent2"><span class="glyph">•</span>The proportion who walked independently was 18 percent, while those who walked with assistance accounted for 43 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Scoliosis affected 86 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Constipation affected 83 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal breathing patterns were reported for 66 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Anticonvulsant medications were used by 64 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Sleep disturbance affected 63 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Low weight for age was present in 53 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Gallbladder disorders affected 5 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A Danish longitudinal study of 24 females with RTT with a mean age of 44 years who were followed for roughly a decade reported the following outcomes [<a href="#rid63">63</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Eighty-eight percent lived at a residential facility</p><p class="bulletIndent2"><span class="glyph">•</span>One hundred percent had a decline in gross motor skills with age; however, 58 percent retained the ability to walk unassisted or with support</p><p class="bulletIndent2"><span class="glyph">•</span>Eighty-seven percent had scoliosis, and two underwent spinal fusion surgery to address complications arising from severe scoliosis</p><p class="bulletIndent2"><span class="glyph">•</span>Seventy-nine percent were diagnosed with epilepsy</p><p class="bulletIndent2"><span class="glyph">•</span>Thirty-eight percent received antidepressant or antipsychotic medications</p><p class="bulletIndent2"><span class="glyph">•</span>Feeding issues were prevalent, with 20.8 percent being fed by gastrostomy tube</p><p></p><p class="headingAnchor" id="H2567520501"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122569.html" rel="external">"Society guideline links: Rett syndrome"</a>.)</p><p class="headingAnchor" id="H77344523"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosocial support</strong> – Rett syndrome (RTT) has a tremendous impact on affected individuals, families, and caregivers. Most individuals require intensive health care support and live at home throughout adulthood, leading to a life-long burden on families and caregivers. The well-being of RTT caregivers should be assessed, and they should be encouraged to take time off and use respite care as needed for their own mental and physical health. Resources and information are available from organization listed above. (See <a class="local">'Counseling and support'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease-modifying therapy</strong> – <a class="drug drug_general" data-topicid="140989" href="/z/d/drug information/140989.html" rel="external">Trofinetide</a> is the first disease-modifying therapy for RTT. Given limitations of the evidence (modest benefit in short-term trials and absence of long-term data), treatment decisions regarding trofinetide should be individualized and guided by shared decision-making involving the treating clinician, family, and caregivers. Trofinetide is dosed according to patient weight, as described above. The most common adverse effect is diarrhea. (See <a class="local">'Trofinetide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Symptomatic management of RTT consists of treating the associated conditions. A multidisciplinary approach is optimal. A program of physical, occupational, and communication therapy should be provided. Specific issues that commonly require attention include (see <a class="local">'Management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Growth and nutrition (see <a class="local">'Nutrition'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal (see <a class="local">'Gastrointestinal dysfunction'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Bone health (see <a class="local">'Bone quality and fractures'</a> above and <a class="local">'Scoliosis'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Epilepsy (see <a class="local">'Seizures'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Breathing dysfunction (see <a class="local">'Breathing disturbances'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac abnormalities (see <a class="local">'Cardiac abnormalities'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Sleep disturbance (see <a class="local">'Sleep disturbance'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Motor dysfunction (see <a class="local">'Motor dysfunction'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history</strong> – The natural history of typical RTT is notable for a period of normal development for the first 6 to 18 months of life followed by a regression phase, with partial or complete loss of speech and purposeful hand use, and onset of stereotypic hand movements, gait abnormalities, and other manifestations. The regression phase is followed by a period of some recovery of nonverbal communication, but the long-term course is one of a slow deterioration in gross motor function. Respiratory illnesses and seizure-related conditions are the most common causes of death. However, most patients with RTT survive into adulthood. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2731405917"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Daniel G Glaze, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatr Open 2020; 4:e000717.</a></li><li><a class="nounderline abstract_t">Byiers BJ, Dimian A, Symons FJ. Functional communication training in rett syndrome: a preliminary study. Am J Intellect Dev Disabil 2014; 119:340.</a></li><li><a class="nounderline abstract_t">Lane JB, Salter AR, Jones NE, et al. Assessment of Caregiver Inventory for Rett Syndrome. J Autism Dev Disord 2017; 47:1102.</a></li><li><a class="nounderline abstract_t">Laurvick CL, Msall ME, Silburn S, et al. Physical and mental health of mothers caring for a child with Rett syndrome. Pediatrics 2006; 118:e1152.</a></li><li class="breakAll">FDA approves first treatment for Rett syndrome. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-rett-syndrome (Accessed on March 30, 2023).</li><li><a class="nounderline abstract_t">Glaze DG, Neul JL, Kaufmann WE, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology 2019; 92:e1912.</a></li><li><a class="nounderline abstract_t">Silva-Reis SC, Sampaio-Dias IE, Costa VM, et al. Concise Overview of Glypromate Neuropeptide Research: From Chemistry to Pharmacological Applications in Neurosciences. ACS Chem Neurosci 2023; 14:554.</a></li><li class="breakAll">Daybue (trofinetide) oral solution prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217026s000lbl.pdf (Accessed on March 29, 2023).</li><li><a class="nounderline abstract_t">Neul JL, Percy AK, Benke TA, et al. Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome. Contemp Clin Trials 2022; 114:106704.</a></li><li class="breakAll">Daybue (trofinetide): Key facts for parents. Available at: https://reverserett.org/news/articles/daybue-trofinetide-key-facts-for-parents/ (Accessed on April 17, 2023).</li><li><a class="nounderline abstract_t">Glaze DG, Neul JL, Percy A, et al. A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome. Pediatr Neurol 2017; 76:37.</a></li><li class="breakAll">Acadia pharmaceuticals announces positive top-line results from the pivotal phase 3 Lavender trial of trofinetide in Rett syndrome. Acadia Pharmaceuticals Inc. https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-positive-top-line-results-from-the-pivotal-phase-3-lavender-trial-of-trofinetide-in-rett-syndrome (Accessed on April 16, 2023).</li><li><a class="nounderline abstract_t">Buchovecky CM, Turley SD, Brown HM, et al. A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat Genet 2013; 45:1013.</a></li><li><a class="nounderline abstract_t">Percy AK. Neuroscience. Path to treat Rett syndrome. Science 2013; 342:318.</a></li><li><a class="nounderline abstract_t">Noutel J, Hong YK, Leu B, et al. Experience-dependent retinogeniculate synapse remodeling is abnormal in MeCP2-deficient mice. Neuron 2011; 70:35.</a></li><li><a class="nounderline abstract_t">Djukic A, Holtzer R, Shinnar S, et al. Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate. Pediatr Neurol 2016; 61:51.</a></li><li><a class="nounderline abstract_t">Bassuk AG. Gene therapy for Rett syndrome. Genes Brain Behav 2022; 21:e12754.</a></li><li><a class="nounderline abstract_t">Collins BE, Merritt JK, Erickson KR, Neul JL. Safety and efficacy of genetic MECP2 supplementation in the R294X mouse model of Rett syndrome. Genes Brain Behav 2022; 21:e12739.</a></li><li><a class="nounderline abstract_t">Vermudez SAD, Gogliotti RG, Arthur B, et al. Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model. Genes Brain Behav 2022; 21:e12752.</a></li><li class="breakAll">Safety and Efficacy of TSHA-102 in Adult Females With Rett Syndrome (REVEAL Adult Study). Clinicaltrials.gov. US National Library of Medicine. November 9, 2022. Available at: https://clinicaltrials.gov/ct2/show/NCT05606614 (Accessed on December 04, 2022).</li><li><a class="nounderline abstract_t">Leonard H, Ravikumara M, Baikie G, et al. Assessment and management of nutrition and growth in Rett syndrome. J Pediatr Gastroenterol Nutr 2013; 57:451.</a></li><li><a class="nounderline abstract_t">Motil KJ, Morrissey M, Caeg E, et al. Gastrostomy placement improves height and weight gain in girls with Rett syndrome. J Pediatr Gastroenterol Nutr 2009; 49:237.</a></li><li><a class="nounderline abstract_t">Motil KJ, Khan N, Coon JL, et al. Gastrointestinal Health Questionnaire for Rett Syndrome: Tool Development. J Pediatr Gastroenterol Nutr 2021; 72:354.</a></li><li><a class="nounderline abstract_t">Jefferson A, Leonard H, Siafarikas A, et al. Clinical Guidelines for Management of Bone Health in Rett Syndrome Based on Expert Consensus and Available Evidence. PLoS One 2016; 11:e0146824.</a></li><li><a class="nounderline abstract_t">Baim S, Leonard MB, Bianchi ML, et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom 2008; 11:6.</a></li><li><a class="nounderline abstract_t">Bishop N, Arundel P, Clark E, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom 2014; 17:275.</a></li><li><a class="nounderline abstract_t">Downs J, Bergman A, Carter P, et al. Guidelines for management of scoliosis in Rett syndrome patients based on expert consensus and clinical evidence. Spine (Phila Pa 1976) 2009; 34:E607.</a></li><li><a class="nounderline abstract_t">Harrison DJ, Webb PJ. Scoliosis in the Rett syndrome: natural history and treatment. Brain Dev 1990; 12:154.</a></li><li><a class="nounderline abstract_t">Bassett GS, Tolo VT. The incidence and natural history of scoliosis in Rett syndrome. Dev Med Child Neurol 1990; 32:963.</a></li><li><a class="nounderline abstract_t">Thorey F, Jäger M, Seller K, et al. How to prevent small stature in Rett syndrome-associated collapsing spine syndrome. J Child Neurol 2007; 22:443.</a></li><li><a class="nounderline abstract_t">Kerr AM, Webb P, Prescott RJ, Milne Y. Results of surgery for scoliosis in Rett syndrome. J Child Neurol 2003; 18:703.</a></li><li><a class="nounderline abstract_t">Downs J, Torode I, Wong K, et al. Surgical fusion of early onset severe scoliosis increases survival in Rett syndrome: a cohort study. Dev Med Child Neurol 2016; 58:632.</a></li><li><a class="nounderline abstract_t">Krajnc N, Župančič N, Oražem J. Epilepsy treatment in Rett syndrome. J Child Neurol 2011; 26:1429.</a></li><li><a class="nounderline abstract_t">Jian L, Nagarajan L, de Klerk N, et al. Seizures in Rett syndrome: an overview from a one-year calendar study. Eur J Paediatr Neurol 2007; 11:310.</a></li><li><a class="nounderline abstract_t">Haas RH, Rice MA, Trauner DA, Merritt TA. Therapeutic effects of a ketogenic diet in Rett syndrome. Am J Med Genet Suppl 1986; 1:225.</a></li><li><a class="nounderline abstract_t">Liebhaber GM, Riemann E, Baumeister FA. Ketogenic diet in Rett syndrome. J Child Neurol 2003; 18:74.</a></li><li><a class="nounderline abstract_t">Giampietro PF, Schowalter DB, Merchant S, et al. Widened clinical spectrum of the Q128P MECP2 mutation in Rett syndrome. Childs Nerv Syst 2006; 22:320.</a></li><li><a class="nounderline abstract_t">Valencia I, Holder DL, Helmers SL, et al. Vagus nerve stimulation in pediatric epilepsy: a review. Pediatr Neurol 2001; 25:368.</a></li><li><a class="nounderline abstract_t">Wilfong AA, Schultz RJ. Vagus nerve stimulation for treatment of epilepsy in Rett syndrome. Dev Med Child Neurol 2006; 48:683.</a></li><li><a class="nounderline abstract_t">Gökben S, Ardıç UA, Serdaroğlu G. Use of buspirone and fluoxetine for breathing problems in Rett syndrome. Pediatr Neurol 2012; 46:192.</a></li><li><a class="nounderline abstract_t">Ohno K, Saito Y, Ueda R, et al. Effect of Serotonin 1A Agonists and Selective Serotonin Reuptake Inhibitors on Behavioral and Nighttime Respiratory Symptoms in Rett Syndrome. Pediatr Neurol 2016; 60:54.</a></li><li><a class="nounderline abstract_t">Levitt ES, Hunnicutt BJ, Knopp SJ, et al. A selective 5-HT1a receptor agonist improves respiration in a mouse model of Rett syndrome. J Appl Physiol (1985) 2013; 115:1626.</a></li><li><a class="nounderline abstract_t">Abdala AP, Lioy DT, Garg SK, et al. Effect of Sarizotan, a 5-HT1a and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome. Am J Respir Cell Mol Biol 2014; 50:1031.</a></li><li class="breakAll">Evaluation of the efficacy, safety, and tolerability of sarizotan in Rett syndrome with respiratory symptoms. https://clinicaltrials.gov/ct2/show/NCT02790034 (Accessed on August 06, 2019).</li><li><a class="nounderline abstract_t">Jan JE, Owens JA, Weiss MD, et al. Sleep hygiene for children with neurodevelopmental disabilities. Pediatrics 2008; 122:1343.</a></li><li><a class="nounderline abstract_t">Blackmer AB, Feinstein JA. Management of Sleep Disorders in Children With Neurodevelopmental Disorders: A Review. Pharmacotherapy 2016; 36:84.</a></li><li><a class="nounderline abstract_t">Piazza CC, Fisher W, Moser H. Behavioral treatment of sleep dysfunction in patients with the Rett syndrome. Brain Dev 1991; 13:232.</a></li><li class="breakAll">Ferber R, Kryger M. Principles and Practice of Sleep Medicine in the Child, 1st ed, WB Saunders, Philadelphia 1995.</li><li><a class="nounderline abstract_t">McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. Dev Med Child Neurol 1998; 40:186.</a></li><li><a class="nounderline abstract_t">Miyamoto A, Oki J, Takahashi S, Okuno A. Serum melatonin kinetics and long-term melatonin treatment for sleep disorders in Rett syndrome. Brain Dev 1999; 21:59.</a></li><li><a class="nounderline abstract_t">Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998; 351:1254.</a></li><li><a class="nounderline abstract_t">Lotan M, Isakov E, Merrick J. Improving functional skills and physical fitness in children with Rett syndrome. J Intellect Disabil Res 2004; 48:730.</a></li><li><a class="nounderline abstract_t">Lotan M, Hanks S. Physical therapy intervention for individuals with Rett syndrome. ScientificWorldJournal 2006; 6:1314.</a></li><li><a class="nounderline abstract_t">Fonzo M, Sirico F, Corrado B. Evidence-Based Physical Therapy for Individuals with Rett Syndrome: A Systematic Review. Brain Sci 2020; 10.</a></li><li><a class="nounderline abstract_t">Hanks SB. Motor disabilities in the Rett syndrome and physical therapy strategies. Brain Dev 1990; 12:157.</a></li><li><a class="nounderline abstract_t">Sharpe PA. Comparative effects of bilateral hand splints and an elbow orthosis on stereotypic hand movements and toy play in two children with Rett syndrome. Am J Occup Ther 1992; 46:134.</a></li><li><a class="nounderline abstract_t">Naganuma GM, Billingsley FF. Effect of hand splints on stereotypic hand behavior of three girls with Rett syndrome. Phys Ther 1988; 68:664.</a></li><li><a class="nounderline abstract_t">Aron M. The use and effectiveness of elbow splints in the Rett syndrome. Brain Dev 1990; 12:162.</a></li><li><a class="nounderline abstract_t">Wigram T, Lawrence M. Music therapy as a tool for assessing hand use and communicativeness in children with Rett Syndrome. Brain Dev 2005; 27 Suppl 1:S95.</a></li><li><a class="nounderline abstract_t">Yasuhara A, Sugiyama Y. Music therapy for children with Rett syndrome. Brain Dev 2001; 23 Suppl 1:S82.</a></li><li><a class="nounderline abstract_t">Elefant C, Wigram T. Learning ability in children with Rett syndrome. Brain Dev 2005; 27 Suppl 1:S97.</a></li><li><a class="nounderline abstract_t">Halbach NS, Smeets EE, Steinbusch C, et al. Aging in Rett syndrome: a longitudinal study. Clin Genet 2013; 84:223.</a></li><li><a class="nounderline abstract_t">Bisgaard AM, Wong K, Højfeldt AK, et al. Decline in gross motor skills in adult Rett syndrome; results from a Danish longitudinal study. Am J Med Genet A 2021; 185:3683.</a></li><li><a class="nounderline abstract_t">Kirby RS, Lane JB, Childers J, et al. Longevity in Rett syndrome: analysis of the North American Database. J Pediatr 2010; 156:135.</a></li><li><a class="nounderline abstract_t">Tarquinio DC, Hou W, Neul JL, et al. The Changing Face of Survival in Rett Syndrome and MECP2-Related Disorders. Pediatr Neurol 2015; 53:402.</a></li><li><a class="nounderline abstract_t">Anderson A, Wong K, Jacoby P, et al. Twenty years of surveillance in Rett syndrome: what does this tell us? Orphanet J Rare Dis 2014; 9:87.</a></li></ol></div><div id="topicVersionRevision">Topic 109840 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32984552" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Consensus guidelines on managing Rett syndrome across the lifespan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25007298" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Functional communication training in rett syndrome: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28132121" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Assessment of Caregiver Inventory for Rett Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16966392" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Physical and mental health of mothers caring for a child with Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16966392" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Physical and mental health of mothers caring for a child with Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30918097" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36735764" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Concise Overview of Glypromate Neuropeptide Research: From Chemistry to Pharmacological Applications in Neurosciences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36735764" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Concise Overview of Glypromate Neuropeptide Research: From Chemistry to Pharmacological Applications in Neurosciences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35149233" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35149233" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28964591" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28964591" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23892605" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24136956" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Neuroscience. Path to treat Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482354" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Experience-dependent retinogeniculate synapse remodeling is abnormal in MeCP2-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27363291" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34053173" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gene therapy for Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33942492" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Safety and efficacy of genetic MECP2 supplementation in the R294X mouse model of Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34002468" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34002468" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084372" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Assessment and management of nutrition and growth in Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19525868" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Gastrostomy placement improves height and weight gain in girls with Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32969958" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gastrointestinal Health Questionnaire for Rett Syndrome: Tool Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26849438" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical Guidelines for Management of Bone Health in Rett Syndrome Based on Expert Consensus and Available Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18442749" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24631254" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644320" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Guidelines for management of scoliosis in Rett syndrome patients based on expert consensus and clinical evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2344012" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Scoliosis in the Rett syndrome: natural history and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2269405" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The incidence and natural history of scoliosis in Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17621526" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : How to prevent small stature in Rett syndrome-associated collapsing spine syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14649553" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Results of surgery for scoliosis in Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26661519" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Surgical fusion of early onset severe scoliosis increases survival in Rett syndrome: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21636780" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Epilepsy treatment in Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17433737" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Seizures in Rett syndrome: an overview from a one-year calendar study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3087185" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Therapeutic effects of a ketogenic diet in Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12661945" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ketogenic diet in Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15875198" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Widened clinical spectrum of the Q128P MECP2 mutation in Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11744311" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Vagus nerve stimulation in pediatric epilepsy: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16836782" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Vagus nerve stimulation for treatment of epilepsy in Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22353299" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Use of buspirone and fluoxetine for breathing problems in Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27212420" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of Serotonin 1A Agonists and Selective Serotonin Reuptake Inhibitors on Behavioral and Nighttime Respiratory Symptoms in Rett Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092697" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A selective 5-HT1a receptor agonist improves respiration in a mouse model of Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24351104" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of Sarizotan, a 5-HT1a and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24351104" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effect of Sarizotan, a 5-HT1a and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047255" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sleep hygiene for children with neurodevelopmental disabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26799351" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Management of Sleep Disorders in Children With Neurodevelopmental Disorders: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1957971" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Behavioral treatment of sleep dysfunction in patients with the Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1957971" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Behavioral treatment of sleep dysfunction in patients with the Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9566656" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10082254" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Serum melatonin kinetics and long-term melatonin treatment for sleep disorders in Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9643754" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pro-convulsant effects of oral melatonin in neurologically disabled children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494062" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Improving functional skills and physical fitness in children with Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17041720" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Physical therapy intervention for individuals with Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32630125" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Evidence-Based Physical Therapy for Individuals with Rett Syndrome: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2344013" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Motor disabilities in the Rett syndrome and physical therapy strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1595824" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparative effects of bilateral hand splints and an elbow orthosis on stereotypic hand movements and toy play in two children with Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3362979" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of hand splints on stereotypic hand behavior of three girls with Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2344014" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The use and effectiveness of elbow splints in the Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182499" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Music therapy as a tool for assessing hand use and communicativeness in children with Rett Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11738847" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Music therapy for children with Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182495" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Learning ability in children with Rett syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23167724" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Aging in Rett syndrome: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34296518" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Decline in gross motor skills in adult Rett syndrome; results from a Danish longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19772971" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Longevity in Rett syndrome: analysis of the North American Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26278631" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The Changing Face of Survival in Rett Syndrome and MECP2-Related Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24942262" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Twenty years of surveillance in Rett syndrome: what does this tell us?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
